Interim report 2026
Filed with HKEX · Stock code 9939 · · 116 pages · English and Chinese
Corporate Information 公司資料 Financial and Business Highlights 財務與業務摘要 Management Discussion and Analysis 管理層討論與分析 Interim Condensed Consolidated Statement of Comprehensive Income 中期簡明綜合全面收益表 Interim Condensed Consolidated Statement of Financial Position 中期簡明綜合財務狀況表 2 Interim Condensed Consolidated Statement of Changes in Equity 54 中期簡明綜合權益變動表 5 Interim Condensed Consolidated Statement of Cash Flows
Kintor Pharmaceutical Ltd on 6ix
Earlier from Kintor Pharmaceutical
- Resignation of chief financial officer, joint company secretary and process agent, appointment of chief financial officer and appointment of process agent
- Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
- Kintor Pharmaceutical: Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine
- Kintor Pharmaceutical: Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
- Kintor Pharmaceutical: Pharma Announces 2023 Interim Results and Recent Business Highlights
Later from Kintor Pharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - receipt of notice of grant of invention patent for KT-939
- Update on measures and actions taken in resolving the disclaimer of opinion in the annual report for the year ended 31 December 2025
Follow Kintor Pharmaceutical into a list and get an email when it puts out news.
Follow Kintor Pharmaceutical